ClinicalTrials.gg
CompletedNCT06522997ALPINE 1Updated Apr 13, 2026

A Study to Learn About How Well BAY3283142 Works and Its Safety in Participants With Chronic Kidney Disease

A Phase 2 interventional study of BAY3283142 and Placebo in Chronic Kidney Disease, sponsored by Bayer. Completed at 153 sites in 15 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-04-13.

Sponsored by Bayer · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Oct 2025, 1 year ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
1,222
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 49 studies in Renal Insufficiency, Chronic by Bayer — 4 open to participants now, 8 under way, 2 of them phase 3. Renal Insufficiency, Chronic · Bayer.

Enrollment
3rd of 32
1,222 · median 98
Started
2024
with 6 others
Phase 2
10 of 49
none open now
Registered
41st of 49
by date

Among the 49 studies in Renal Insufficiency, Chronic by Bayer, this one is the 3rd largest by enrollment of the 32 interventional ones that give a count, is one of 7 that started in 2024, is one of 10 in phase 2, and was the 41st registered.

Renal Insufficiency, Chronic

3,096 studies on the registry are indexed under Renal Insufficiency, Chronic; 701 are open to participants now.

Browse Renal Insufficiency, Chronic studies →

Open to participants now

4 of the 49 studies in Renal Insufficiency, Chronic by Bayer are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Who these studies take

Of the 435 Renal Insufficiency, Chronic studies recruiting now, 245 (56%) set no upper age limit and 110 (25%) stop at 75 or younger; 44 take children under 18; 80 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 49 studies in Renal Insufficiency, Chronic by Bayer, or all of them as a file.
02

Study summary

Researchers are looking for a better way to treat people who have chronic kidney disease (CKD), CKD is a condition in which the kidneys' ability to work properly gradually decreases over time. A common sign of decreasing kidney function is the body losing too much of a protein called albumin in the urine. This condition is known as albuminuria. This can lead to a faster decline in kidney function. People who have high blood pressure and diabetes are more likely to have CKD and are at a higher risk of complications related to it.

BAY3283142 is a new drug that is being developed to treat people with CKD. It works by activating a protein that helps relax blood vessels and is thought to have beneficial effects in CKD.

In this study, researchers want to learn about how well different doses of BAY3283142 work when taken with standard treatment for CKD in reducing albumin in the urine of participants with CKD. They will compare the results of the change in the urine albumin-creatinine ratio (UACR) after 16 weeks for BAY3283142 with a placebo. A placebo looks like the study drug but does not have any medicine in it.

During the study, participants will take either of the following drugs:

  • BAY3283142: Participants will take BAY3283142 as tablets by mouth.
  • Placebo: Participants will take it in the same way as BAY3283142. Participants will continue taking the available standard treatment for CKD and other conditions they may have (for example, heart conditions and diabetes).

At the start of this study, the researchers will check the medical history and current medications of the participants. They will also perform a complete health check-up of all the participants. Researchers will take urine and blood samples from the participants at different time points to measure UACR and eGFR.

Participants will be divided equally into different groups. Only 1 group will receive placebo and the other groups will receive BAY3283142. Participants will take their assigned treatment for 16 weeks.

No one will know who receives which drug or dose of BAY3283142 during the study.

Participants will be in this study for around 23 weeks. This includes the time for screening before the start of treatment and follow-up with participants after treatment.

People can join this study if they:

  • are 18 years of age or older and have been diagnosed with CKD
  • have poor kidney function according to the eGFR test
  • have abnormally high levels of albumin in the urine according to the UACR test
  • have been taking certain drugs at a stable dose for management of high blood pressure, diabetes, kidney disease, etc. for at least 4 weeks before the start of the study

People cannot join this study if they:

  • have low blood pressure
  • have had a stroke or a heart attack, or were hospitalized because of heart failure in the 3 months before the start of the study
  • have a serious liver disease
  • have a kidney disease for which they need to take drugs that control the immune system The detailed requirements will be discussed between the study doctors and people considering joining this study.

Participants may or may not get the expected benefits of treatment with BAY3283142, but they will receive thorough medical check-ups during this study. These can help to improve individual treatment in the future and to identify unknown medical risks.

Some participants may experience medical problems during this study including pain and discomfort when blood samples are taken. Researchers will closely monitor and manage any medical problems the participants may have. They will not include people who should not take BAY3283142 due to known safety concerns.

The findings from this study may contribute to developing a new treatment option for people with CKD who have excess albumin in the urine.

03

Conditions studied

  • Chronic Kidney Disease
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participant must be ≥18 years of age
  • (Chronic Kidney Disease Epidemiology Collaboration formula) ≥20 and ≤75 mL/min /1.73 m\^2 at Screening Note: One re-assessment of eGFR based on central laboratory values is allowed during the Screening period"
  • UACR ≥200 mg/g and \<3500 mg/g as determined by the geometric mean (as calculated by the central laboratory) of 3 morning void urine specimens obtained at Screening
  • Treatment with the highest tolerated labeled dose of either angiotensin-converting enzyme inhibitor (ACEI) or angiotensin receptor blockers (ARB), unless such treatment is either not tolerated or . Treatment dose must be stable dose for at least 4 weeks before Screening with no planned change of the therapy during the study
  • If the participant receives any of the following treatments it should be stable for 4 weeks prior to Screening: sodium-glucose co-transporter-2 (SGLT2) inhibitor, finerenone, diuretics, endothelin-receptor antagonists, or glucagon-like peptide (GLP) receptor agonist

Exclusion criteria

Exclusion Criteria:

  • Systolic blood pressure (SBP) \<100 mmHg at Visit 2 (baseline)
  • Patients with a tendency for orthostatic hypotension at Screening and Visit 2 (baseline) as judged by the investigator
  • SBP ≥160 mmHg, unless treated with ≥3 blood pressure lowering medications, at Screening or at Visit 2 (baseline)
  • History of secondary hypertension other than CKD
  • Hepatic impairment corresponding to B or C or other significant liver disease (e.g., acute hepatitis, chronic active hepatitis, cirrhosis as indicated by e.g. or ALT >3x or total >2x ULN) at Screening
  • Polycystic kidney disease, lupus nephritis or ANCA-associated vasculitis and any other kidney disease requiring therapy within 6 months prior to Screening
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
1,222 participants (actual)

Study arms

  • Placebo comparator
    Arm 1

    Placebo OD and sham titration after 14 days and after 28 days

    Drug: Placebo

  • Experimental
    Arm 2

    BAY3283142 (dose 1) OD and sham titration after 14 days and after 28 days

    Drug: BAY3283142

  • Experimental
    Arm 3

    BAY3283142 (dose 2) OD and sham titration after 14 days and after 28 days

    Drug: BAY3283142

  • Experimental
    Arm 4

    BAY3283142 (dose 2) OD and uptitration to dose 3 OD after 14 days and sham titration after 28 days

    Drug: BAY3283142

  • Experimental
    Arm 5

    BAY3283142 (dose 2) OD and uptitration to dose 3 OD after 14 days and to dose 4 OD after 28 days

    Drug: BAY3283142

  • Experimental
    Arm 6

    BAY3283142 (dose 3) OD and uptitration to dose 5 OD after 14 days and sham titration after 28 days

    Drug: BAY3283142

Interventions

  • Tablet, intake orally once daily

  • DrugPlacebo

    Matching with BAY3283142

06

What researchers measure

Primary outcomes

  1. Change from baseline to Week 16 in the logarithm of urine albumin-creatinine ratio (UACR)

    Time frame: From baseline to Week 16

Secondary outcomes

  1. Change from baseline over time in estimated glomerular filtration rate (eGFR)

    Time frame: From baseline to Week 16

  2. Change from baseline over time in the logarithm of UACR

    Time frame: From baseline to Week 16

  3. Number of participants with treatment-emergent adverse events (TEAEs), serious TEAEs, and TEAEs leading to permanent discontinuation of study intervention

    Time frame: From the first dose of study intervention up to 7 days after last intake of study intervention, up to 17 Weeks per each participant

07

Study locations

153 sites
  • Nephrology Consultants, LLC
    Huntsville, Alabama 35805, United States
  • Balboa Research SMO+ - Chula Vista
    Chula Vista, California 91910, United States
  • California Kidney Specialists - San Dimas
    San Dimas, California 91773, United States
  • Yale Nephrology Clinical Research Clinic
    New Haven, Connecticut 06510, United States
  • Nova Clinical Research - Blake Medical Center
    Bradenton, Florida 34209, United States
  • Renstar Medical Research - Deerwood Clinic
    Ocala, Florida 34471, United States
  • Elixia Central Florida
    Orlando, Florida 32608, United States
  • Florida Institue for Clinical Research
    Orlando, Florida 32825, United States
  • Southeastern Clinical Research Institute, LLC
    Augusta, Georgia 30904, United States
  • Research by Design, LLC | Chicago, IL
    Chicago, Illinois 60643, United States
  • Nephrology Associates of Northern Illinois and Indiana - Hinsdale
    Hinsdale, Illinois 60521, United States
  • Triad Internal Medicine - Asheboro
    Asheboro, North Carolina 27203, United States
  • Eastern Nephrology Associates - New Bern
    New Bern, North Carolina 28562, United States
  • Brookview Hills Research Associates, LLC
    Winston-Salem, North Carolina 27103, United States
  • Knoxville Kidney Center, PLLC
    Knoxville, Tennessee 37923, United States
  • Vanderbilt University Medical Center - Nephrology Clinical Trials Center
    Nashville, Tennessee 37232, United States
  • Renal Disease Research Institute | Landry
    Dallas, Texas 75246, United States
  • Southwest Houston Research, Ltd.
    Houston, Texas 77099, United States
  • Clinical Advancement Center, PLLC
    San Antonio, Texas 78212, United States
  • Utah Kidney Research Institute | Salt Lake City, UT
    South Salt Lake, Utah 84115, United States
  • Peninsula Kidney Associates - Hampton
    Hampton, Virginia 23666, United States
  • Manassas Clinical Research Center
    Manassas, Virginia 20110, United States
  • Salem VA Medical Center - Nephrology
    Salem, Virginia 24153, United States
  • Mendez Center For Clinical Research | Woodbridge, VA
    Woodbridge, Virginia 22192, United States
  • Centro de Investigaciones Metabolicas | Ciudad de Autonoma de Buenos Aires, Argentina
    Ciudad Autónoma de Buenos Aire, Buenos Aires C1056ABI, Argentina
  • Centro de Investigaciones Medicas Temperley | Buenos Aires, Argentina
    Temperley, Buenos Aires B1834GUK, Argentina
  • CEDIC Centro de Investigación Clínica | Buenos Aires, Argentina
    CABA, Ciudad Auton. de Buenos Aires C1018DES, Argentina
  • Centro de Especialidades Medicas (Cemedic) | Cardiology Department
    Villa Luro, Ciudad Auton. de Buenos Aires C1440CFD, Argentina
  • Centro de Rehabilitacion Cardiovascular | San Luis, Argentina
    San Luis, San Luis Province D5700CGR, Argentina
  • Centro de Educacion Medica e Investigaciones Clinicas "Norberto Quirno" (CEMIC)
    Buenos Aires, C1431FWO, Argentina
  • Centro Privado San Vicente Diabetes
    Córdoba, 5000, Argentina
  • Fundacion Centro de Salud e Investigaciones Medicas | Santa Rosa, Argentina
    Santa Rosa, 0, Argentina
  • Epicura / Nephrology
    Baudour, 7331, Belgium
  • UZ Gent / Nephrology
    Ghent, 9000, Belgium
  • Jan Yperman Ziekenhuis / Nephrology
    Ieper, 8900, Belgium
  • UZ Brussel Nephrology
    Jette, 1090, Belgium
  • UZ Leuven / Nephrology
    Leuven, 3000, Belgium
  • AZ Delta / Nephrology
    Roeselare, 8800, Belgium
  • The First Affiliated Hospital of Xiamen University
    Xiamen, Fujian 361003, China
  • The First Affiliated Hospital of Guangzhou University of TCM
    Guangzhou, Guangdong 510405, China
  • The Third Xiangya Hospital of Central South University
    Changsha, Hunan 410013, China
  • Huai'an First People's Hospital, Nanjing Medical University
    Huai'an, Jiangsu 223300, China
  • The Second Affiliated Hospital of Nanjing Medical university
    Nanjing, Jiangsu 210011, China
  • The Second Hospital of Jilin University
    Changchun, Jilin 130000, China
  • Shandong Provincial Hospital
    Jinan, Shandong 250021, China
  • Taizhou Hospital of Zhejiang Province
    Taizhou, Zhejiang 317099, China
  • Capital Medical University (CMU) - Beijing Anzhen Hospital (BAH)
    Beijing, 100029, China
  • Peking University People's Hospital
    Beijing, 100044, China
  • Sichuan University - West China Hospital
    Chengdu, 610041, China
  • Sichuan Academy of Medical Sciences & Sichuan Provincial People's Hospital (SAMSPH)
    Chengdu, 610072, China
  • The First People's Hospital - Foshan
    Foshan, 528000, China
  • Southern Medical University - Nanfang Hospital (Southern Hospital)
    Guangzhou, 510515, China
  • Jiangsu Province Hospital of Traditional Chinese Medicine (TCM)
    Nanjing, 210029, China
  • Renji Hospital Shanghai JiaoTong University of Medicine
    Shanghai, 200001, China
  • Huadong Hospital, Affiliated to Fudan University
    Shanghai, 200040, China
  • Shanxi Bethune Hospital
    Taiyuan, 030032, China
  • University General Hospital of Patras | Nephrology Clinic
    Pátrai, Achaia 26504, Greece
  • General Hospital Of Thessaloniki Papageorgiou-Renal Department
    Efkarpia, Thessaloniki 56429, Greece
  • Laiko General Hospital Of Athens_ Department of Nephrology and Renal Transplantation
    Athens, 11525, Greece
  • University General Hospital of Heraklion-Nephrology Clinic
    Heraklion, 71500, Greece
  • University General Hospital Of Ioannina-Nephrology Clinic
    Ioannina, 45500, Greece
  • General University Hospital Of Larissa-Nephrology Clinic
    Larissa, 41100, Greece
  • Ippokratio General Hospital Of Thessaloniki- 1st Department of Nephrology
    Thessaloniki, 54642, Greece
  • Geniko Nosokomeio Thessalonikis George Papanikolaou-Nephrology Department
    Thessaloniki, 57010, Greece
  • Mavani Research Center
    Ahmedabad, Gujarat 380052, India
  • Life Care Clinic (LifeCare Clinic & Research Centre (LCRC))
    Bengaluru, Karnataka 560092, India
  • Max Super Speciality Hospital, Saket (West Block), (A unit of Max Healthcare Institute Limited)
    New Delhi, National Capital Territory of Delhi 110017, India
  • All India Institute of Medical Sciences (AIIMS) - New Delhi
    New Delhi, National Capital Territory of Delhi 110029, India
  • Madras Diabetes Research Foundation
    Chennai, Tamil Nadu 600086, India
  • The Institute of Post Graduate Medical Education & Research (IPGMER) (SSKM Hospital)
    Kolkata, West Bengal 700020, India
  • Azienda Ospedaliero-Universitaria Di Bologna IRCCS_Policlinico Sant'Orsola - Nefrologia, Dialisi e Trapianto
    Bologna, Emilia-Romagna 40138, Italy
  • ASST Papa Giovanni XXIII | Ospedale di Bergamo - SC Malattie Endocrine-Diabetologia
    Bergamo, 24127, Italy
  • Azienda Ospedaliera Universitaria Gaetano Martino Messina - Nefrologia e Dialisi
    Messina, 98124, Italy
  • Azienda Ospedaliero Universitaria di Modena_Policlinico - Nefrologia, Dialisi e Trapianto di Rene
    Modena, 41124, Italy
  • Istituti Clinici Scientifici Maugeri S.p.A._Pavia - Nefrologia
    Pavia, 27100, Italy
  • Kasugai Municipal Hospital
    Kasugai, Aichi-ken 486-8510, Japan
  • Chubu Rosai Hospital
    Nagoya, Aichi-ken 455-8530, Japan
  • Juntendo University Urayasu Hospital
    Urayasu, Chiba 279-0021, Japan
  • Ehime Prefectural Central Hospital
    Matsuyama, Ehime 790-0024, Japan
  • Saiseikai Matsuyama Hospital
    Matsuyama, Ehime 791-8026, Japan
  • Fukui Prefectural Hospital
    Fukui-shi, Fukui 910-0846, Japan
  • Kokura Memorial Hospital
    Kitakyushu, Fukuoka 802-8555, Japan
  • Steel Memorial Yawata Hospital
    Kitakyushu, Fukuoka 805-8508, Japan
  • Hirohata Naika Clinic
    Kitakyushu, Fukuoka 807-0857, Japan
  • Jiyugaoka Yamada Internal Medicine Clinic
    Obihiro, Hokkaido 080-0848, Japan
  • Naka Kinen Clinic
    Naka, Ibaraki 311-0113, Japan
  • Komatsu Municipal Hospital
    Komatsu, Ishikawa-ken 923-8560, Japan
  • Shonan Kamakura General Hospital
    Kamakura, Kanagawa 247-8533, Japan
  • Saiseikai Yokohamashi Nanbu Hospital
    Yokohama, Kanagawa 234-0054, Japan
  • Yokohama City University Hospital
    Yokohama, Kanagawa 236-0004, Japan
  • Katta General Hospital
    Shiroishi, Miyagi 989-0231, Japan
  • Rinku General Medical Center
    Izumisano, Osaka 598-8577, Japan
  • Hamamatsu University Hospital
    Hamamatsu, Shizuoka 431-3192, Japan
  • NTT Medical Center Tokyo
    Shinagawa-ku, Tokyo 141-8625, Japan
  • University of Yamanashi Hospital
    Chūō, Yamanashi 409-3898, Japan
  • Japanese Red Cross Fukuoka Hospital
    Fukuoka, 815-8555, Japan
  • Nara Prefecture General Medical Center
    Nara, 630-8581, Japan
  • Osaka General Medical Center
    Osaka, 558-8558, Japan
  • Japanese Red Cross Saitama Hospital
    Saitama, 330-8553, Japan
  • Unidade Local De Saúde De Lisboa Ocidental E.P.E.
    Carnaxide, Lisbon District 2790-134, Portugal

Showing the first 100 of 153 sites across 15 countries. Choose a country and city above to see the rest.

08

References and documents

Individual participant data

Plan to share: No — Availability of this study's data will later be determined according to Bayer's commitment to the EFPIA/PhRMA "Principles for responsible clinical trial data sharing". This pertains to scope, timepoint and process of data access. As such, Bayer commits to sharing upon request from qualified researchers' patient-level clinical trial data, study-level clinical trial data, and protocols from clinical trials in patients for medicines and indications approved in the US and EU as necessary for conducting legitimate research. This applies to data on new medicines and indications that have been approved by the EU and US regulatory agencies on or after January 01, 2014. Interested researchers can use www.vivli.org to request access to anonymized patient-level data and supporting documents from clinical studies to conduct research. Information on the Bayer criteria for listing studies and other relevant information is provided in the Study sponsors section of the portal.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2024 to primary completion in Oct 2025, 14 months.

Of 80 industry-sponsored phase 2 interventional studies under Renal Insufficiency, Chronic, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 31. This study's 14 months is below that.

Counting every sponsor, half of 139 studies reached it within 25 months; a quarter within 15 and three quarters within 43.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 22, 2024
First posted
Jul 26, 2024
StartActual
Aug 8, 2024
Primary completionActual
Oct 24, 2025
CompletionActual
Nov 20, 2025
Last update
Apr 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 13, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06522997
Lead sponsor
Bayer
Responsible party
Sponsor
First posted
Jul 26, 2024
Start date
Aug 8, 2024
Primary completion
Oct 24, 2025
Completion
Nov 20, 2025
Last update
Apr 13, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Nurandociguat

Start the discussion